Cover Kidney News
Volume/Issue:
Volume 14: Issue 2
Page:
15
Publication Date:
01 Feb 2022
Online Publication Date:
04 Feb 2022
  • 1.

    Agarwal R, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021; 385:2507–2519. doi: 10.1056/NEJMoa2110730

  • 2.

    Chertow GM, et al. “Renalism”: Inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 2004; 15:2462–2468. doi: 10.1097/01.ASN.0000135969.33773.0B

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Vogt L, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999–1007. doi: 10.1681/ASN.2007060693

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Trujillo H, et al. The forgotten antiproteinuric properties of diuretics. Am J Nephrol 2021; 52:435–449. doi: 10.1159/000517020

  • 5.

    Kostis JB, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 2011; 306:2588–2593. doi: 10.1001/jama.2011.1821

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Olde Engberink RHG, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality. Hypertension 2015; 65:1033–1040. doi: 10.1161/HYPERTENSIONAHA.114.05122

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Liang W, et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: A meta-analysis. J Cell Mol Med 2017; 21:2634–2642. doi: 10.1111/jcmm.13205

    • Crossref
    • Search Google Scholar
    • Export Citation

“CLICK”ing with Chlorthalidone: Rediscovering an Old Drug for Advanced CKD

Jamie S. Hirsch1
  • 1 Jamie S. Hirsch, MD, is with the Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY. Michael Turk, DO, is a PGY-2 Internal Medicine resident at Allegheny General Hospital, Pittsburgh, PA.
Volume/Issue:
Volume 14: Issue 2
Publication Date:
01 Feb 2022
Page:
15
Restricted access

“There's something special about chlorthalidone.”

–Rajiv Agarwal, MD, as heard on “Freely Filtered”

The nephrology community was abuzz at ASN Kidney Week 2021 as Rajiv Agarwal presented the results of the Chlorthalidone in Chronic Kidney Disease (CLICK) trial, with simultaneous publication in The New England Journal of Medicine (1).

In an attempt to refute the dogma that thiazide-like diuretics lose effectiveness at low estimated glomerular filtration rate (eGFR) (2), the CLICK trial enrolled 160 patients with stage 4 chronic kidney disease (CKD; eGFR 15 to >30 mL/min/1.73 m2) and uncontrolled hypertension—defined as a mean
Save